Healthcare
Live Price
Offline$5.24
+5.86% today
1Y Change
-12.69%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alpha Teknova, Inc. (TKNO) is a Healthcare stock with a market cap of $180.00M and listed on NASDAQ. The stock last traded around $5.24 and down 12.7% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +7.4%, EPS growth of +43.9%, a dividend yield of 0.0%. What stands out right now is revenue +7.4%, EPS +43.9%, free cash flow +31.7% with operating margin -41.9% and ROIC -17.3%. Valuation sits in the middle of the pack at price/sales 4.5. Stock Foundry combines TKNO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TKNO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TKNO Max Drawdown
-68.76%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TKNO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$36.9M
-10.9% YoY
FY Net Income
-$9.8M
+79.3% YoY
Free Cash Flow
-$28.9M
+47.9% YoY
Revenue Growth
+7.4%
EPS Growth
+43.9%
Gross Margin
33.2%
Net Margin
-42.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 41M | 38M | 37M | 41M | 37M |
| Gross Profit | 13M | 7M | 10M | 17M | 18M |
| Operating Income | -17M | -26M | -36M | -50M | -12M |
| EBITDA | -10M | -20M | -26M | -26M | -9M |
| Net Income | -17M | -27M | -37M | -47M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 4M | 28M | 42M | 88M |
| Total Assets | 104M | 119M | 129M | 152M | 167M |
| Total Liabilities | 35M | 36M | 39M | 52M | 23M |
| Shareholder Equity | 69M | 82M | 90M | 100M | 143M |
| Total Debt | 15M | 30M | 30M | 42M | 12M |
| Net Debt | 9M | 26M | 2M | 74K | -76M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+66.9% YoY
Capital Expenditures
20M
+29.4% YoY
Free Cash Flow
29M
+47.9% YoY
Key ratios
Gross Margin
33.2%
Operating Margin
-41.9%
Net Margin
-42.6%
ROE
-23.3%
Debt / Equity
0.22x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.